By VETTAPHARMA reporter – Derek Roche: Simcere Zaiming has entered into an exclusive global licensing agreement with Roche for the development and commercialisation of SIM0660, a tri-specific antibody targeting CD79a, CD19 and CD3 for potential use across B-cell-mediated diseases.
Under the agreement, Roche will acquire exclusive global rights to develop, manufacture and commercialise SIM0660. Simcere Zaiming is eligible to receive up to $1.530 billion in total payments, including a $75 million upfront payment, along with tiered royalties of up to double digits on future net sales.
SIM0660 was developed using Simcere Zaiming’s T-cell engager poly-specific antibody technology. The molecule combines a CD3-engaging arm with binding domains targeting CD79a and CD19, with the aim of inducing T-cell-mediated cytotoxicity while limiting cytokine release.
The company describes SIM0660 as having a potential first-in-class dual-targeting approach against CD79a and CD19. The strategy is designed to provide broad coverage across B-cell-mediated diseases and could offer a differentiated therapeutic approach for patients previously treated with CD20- or CD19-directed therapies.
Beyond oncology, SIM0660 also has potential applications in B-cell-mediated autoimmune diseases, where targeted depletion of pathogenic B cells may provide clinical benefit, according to Simcere Zaiming.
The agreement gives Roche global responsibility for SIM0660 development, manufacturing and commercialisation, while Simcere Zaiming said the collaboration is intended to accelerate the molecule’s clinical development and potentially bring the therapy to patients globally.
The transaction adds to Simcere Pharmaceutical Group’s expanding out-licensing activity. The company said it has now completed six out-licensing transactions, with potential aggregate total consideration exceeding $6.1 billion.
For patients with B-cell-mediated diseases, the potential significance of SIM0660 lies in its dual targeting of CD79a and CD19 combined with CD3-mediated T-cell engagement. The source indicates that this approach could extend beyond patients who have not previously received B-cell-directed therapies and into populations previously treated with CD20- or CD19-directed therapies.
Simcere Zaiming is an oncology-focused biopharmaceutical subsidiary of Simcere Pharmaceutical Group. The company said it has developed a pipeline of clinical assets and launched products in China, while pursuing internal research and development, manufacturing and commercialisation capabilities alongside strategic collaborations.
Quick FAQs
1. What is the disease condition?
SIM0660 is being developed for potential use across B-cell-mediated diseases, including B-cell-mediated cancers and autoimmune diseases.
2. What is the study/trial?
The source does not provide details of a specific clinical trial for SIM0660.
3. What is SIM0660?
SIM0660 is a tri-specific antibody targeting CD79a, CD19 and CD3.
4. How does SIM0660 work?
It combines CD3 engagement with targeting of CD79a and CD19 to induce T-cell-mediated cytotoxicity while limiting cytokine release.
5. What are the financial terms of the Roche agreement?
Simcere Zaiming is eligible for up to $1.530 billion, including $75 million upfront, plus tiered royalties of up to double digits on future net sales.
6. What rights does Roche receive?
Roche receives exclusive global rights to develop, manufacture and commercialise SIM0660.
